[Past, present, and future therapeutically options in age related macular degeneration].
Age related macular degeneration is the most common cause of blindness in patients older than 65 years of age and it ranks second after diabetic retinopathy as the leading cause of blindness in the 45 to 64 years age group. Along the time, an important number of therapeutical options was developed, in association with the pathogenic hypothesis: medication, laser treatment, photodynamic therapy, surgical methods, etc. The goal of this paper is to summarize the evolution of the main therapeutical approaches in age related macular degeneration.
Apostol
Silvia
S
Clinica of Talmologică Ama Optimex Bucureşti.
D000368:Aged; D020256:Choroidal Neovascularization / Q000601:surgery / Q000628:therapy*; D005544:Forecasting; D006801:Humans; D017075:Laser Coagulation / Q000379:methods; D008268:Macular Degeneration / Q000601:surgery / Q000628:therapy*; D008875:Middle Aged; D010778:Photochemotherapy / Q000379:methods; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D000077362:Verteporfin
D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin